%0 Nanopartikel unedler Metalle (Mg0, Al0, Gd0, Sm0) %A Dietlein, Felix %E Mueller, Peter %E Kobe, Carsten %E Endepols, Heike %E Hohberg, Melanie %E Zlatopolskiy, Boris %E Krapf, Philipp %E Heidenreich, Axel %E Neumaier, Bernd %E Drzezga, Alexander %E Dietlein, Markus %I Springer Nature Switzerland %D 2021 %C Cham %T [18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer %U http://juser.fz-juelich.de/record/893306/files/Dietlein2021_Article_%5B18F%5D-JK-PSMA-7PETCTUnderAndro.pdf %X Purpose: PSMA imaging is frequently used for monitoring of androgen deprivation therapy(ADT) in prostate cancer. In a previous study, [18F]-JK-PSMA-7 exhibited favorable propertiesfor tumor localization after biochemical recurrence. In this retrospective study, we evaluated theperformance of [18F]-JK-PSMA-7 under ADT.Procedures: We examined the performance of [18F]-JK-PSMA-7 in 70 patients (first cohort) withincreasing or detectable PSA values under ADT (PSA G 2 ng/ml for 21/70 patients). We furtheranalyzed 58 independent patients with PSA levels G 2 ng/ml under ADT, who were imaged with[68Ga]PSMA-11 or [18F]DCFPyL (second cohort). Finally, we compared detection rates between[18F]-JK-PSMA-7, [68Ga]PSMA-11, and [18F]DCFPyL.Results: In the first cohort, we detected [18F]-JK-PSMA-7-positive lesions in 63/70 patients. Inpatients with PSA levels ≥ 2 ng/ml, the detection rate was 100 % (49/49). In patients with PSA G 2ng/ml, the detection rate was significantly lower (66.7 %, 14/21, p = 9.7 × 10−5) and dropped from85.7%(12/14, PSA levels between 0.3 and 2.0 ng/ml) to 28.6%(2/7) for PSA levels G 0.3 ng/ml (p =1.73 × 10−2). In the second cohort (PSA G 2 ng/ml), the detection rate was 79.3 % (46/58) for[68Ga]PSMA-11 or [18F]DCFPyL. Again, the detection rate was significantly higher (p = 1.1 × 10−2)for patients with PSA levels between 0.3 and 2.0 ng/ml (87.0 %, 40/46) relative to those with PSAlevels G 0.3 ng/ml (50 %, 6/12). No significant difference was found between [18F]-JK-PSMA-7 and[68Ga]PSMA-11 or [18F]DCFPyL in patients with PSA levels G 2 ng/ml (p = 0.4295).Conclusion: [18F]-JK-PSMA-7 PET showed a high detection rate in patients with PSA levels ≥0.3 ng/ml under ADT. The lower PSA threshold of 0.3 ng/ml for high detection rates wasconsistent across the three PSMA ligands. Thus, PSMA imaging is suitable for clinical follow-upof patients with increasing PSA levels under ADT.